Prosolus Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Debt - PPP
- Investors
-
2
Prosolus General Information
Description
Developer a transdermal drug delivery system intended for various therapeutic categories. The company specializes in transdermal patches, pain management, and cardiovascular and neurologic care and manufactures high-barrier-to-entry transdermal drug delivery products, enabling healthcare organizations to treat diseases.
Contact Information
Website
www.prosoluspharma.comCorporate Office
- 6701 North West 7 Street
- Miami, FL 33126
- United States
Corporate Office
- 6701 North West 7 Street
- Miami, FL 33126
- United States
Prosolus Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Debt - PPP | 09-Apr-2020 | Completed | Generating Revenue | |||
| 3. Merger/Acquisition | 02-Aug-2019 | Cancelled | Generating Revenue | |||
| 2. Secondary Transaction - Private | 30-Jun-2018 | Completed | Generating Revenue | |||
| 1. Merger/Acquisition | 29-May-2015 | Completed | Generating Revenue |
Prosolus Comparisons
Industry
Financing
Details
Prosolus Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cure Pharmaceutical | Formerly VC-backed | Oxnard, CA | ||||
| Medherant | Venture Capital-Backed | Coventry, United Kingdom | ||||
| Rottendorf Pharma | Corporation | Ennigerloh, Germany | ||||
| Catalent | Formerly PE-Backed | Somerset, NJ | ||||
| CordenPharma | Private Equity-Backed | Plankstadt, Germany |
Prosolus Patents
Prosolus Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20170340577-A1 | Transdermal drug delivery system | Active | 25-May-2016 | ||
| US-10010511-B2 | Transdermal drug delivery system | Inactive | 25-May-2016 | ||
| US-10307380-B1 | Composition and method for transdermal lidocaine delivery | Inactive | 04-Mar-2014 | ||
| US-9408802-B1 | Seven day drug in adhesive transdermal delivery | Inactive | 22-Mar-2012 | ||
| US-20130214192-A1 | Coated seals | Active | 19-Jul-2007 | C09D4/00 |
Prosolus Executive Team (4)
| Name | Title | Board Seat |
|---|---|---|
| Alejandro Moreno | Co-Founder & Chief Executive Officer | |
| Juan Mantelle | Chief Operating Officer | |
| Kevin Pate | Vice President, Finance |
Prosolus Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Prosolus Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bravos Capital | Venture Capital | Minority | ||
| Mission Pharmacal | Corporation | Majority |
Prosolus FAQs
-
When was Prosolus founded?
Prosolus was founded in 2009.
-
Who is the founder of Prosolus?
Alejandro Moreno is the founder of Prosolus.
-
Who is the CEO of Prosolus?
Alejandro Moreno is the CEO of Prosolus.
-
Where is Prosolus headquartered?
Prosolus is headquartered in Miami, FL.
-
What is the size of Prosolus?
Prosolus has 11 total employees.
-
What industry is Prosolus in?
Prosolus’s primary industry is Drug Delivery.
-
Is Prosolus a private or public company?
Prosolus is a Private company.
-
What is Prosolus’s current revenue?
The current revenue for Prosolus is .
-
Who are Prosolus’s investors?
Bravos Capital and Mission Pharmacal have invested in Prosolus.
-
Who are Prosolus’s competitors?
Cure Pharmaceutical, Medherant, Rottendorf Pharma, Catalent, and CordenPharma are some of the 10 competitors of Prosolus.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
